CSDX / CS Diagnostics Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(g) of The Securities Exchange Act of 1934 CS DIAGNOSTICS CORP. (Exact name of registrant as specified i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(g) of The Securities Exchange Act of 1934 CS DIAGNOSTICS CORP. (Exact name of registrant as specified in its charter) Wyoming 20-1290331 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Stresemannallee 4b

AMENDED AND RESTATED CS DIAGNOSTICS CORP. a Wyoming corporation ARTICLE I

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CS DIAGNOSTICS CORP. a Wyoming corporation ARTICLE I OFFICES Principal Office . The principal office for the transaction of business of the Corporation is hereby fixed and located at Stresemannallee 4c, Neuss, Germany 41460. The location may be changed by approval of a majority of the authorized directors, and additional offices may be established and mai

SECURITIES PURCHASE AGREEMENT

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT, dated as of April 4th , 2022 (this "Agreement") is entered into by and among PatientTrac Limited, an entity organized under the laws of United Kingdom, and its related group, (the "Shareholder"), and CS Diagnostics GmbH, an entity organized under the laws of Germany, its successor or assigns, (the "Purchaser"). The part

CS DIAGNOSTICS CORP A Wyoming Corporation (the “Company”) CERTIFICATE OF DESIGNATION SERIES C PREFERRED STOCK

Exhibit 3.4 CS DIAGNOSTICS CORP A Wyoming Corporation (the “Company”) CERTIFICATE OF DESIGNATION SERIES C PREFERRED STOCK Of the twenty-five million (25,000,000) shares of Preferred Stock, par value $0.00001 per share, authorized pursuant to the Articles of Incorporation, as amended, four million (4,000,000) of such shares are hereby designated as “Series C Preferred Stock.” The powers, designatio

AMENDMENT TO THE ARTICLES OF INCORPORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION SERIES A PREFERRED STOCK CS DIAGNOSTICS CORP.

Exhibit 3.2 AMENDMENT TO THE ARTICLES OF INCORPORATION: ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES A PREFERRED STOCK of CS DIAGNOSTICS CORP. The undersigned, Thomas Graus, hereby certifies that: he is the duly elected and active President and Secretary of CS DIAGNOSTICS CORP., a Wyoming corporation (the “Corporation”). Pursuant to authority given by the Corporation’s Articl

AMENDMENT TO THE ARTICLES OF INCORPORATION ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION SERIES B PREFERRED STOCK CS DIAGNOSTICS CORP.

Exhibit 3.3 AMENDMENT TO THE ARTICLES OF INCORPORATION ARTICLE IV AMENDED & RESTATED CERTIFICATE OF DESIGNATION of SERIES B PREFERRED STOCK of CS DIAGNOSTICS CORP. The undersigned, Thomas Graus, hereby certifies that: he is the duly elected and active President and Secretary of CS DIAGNOSTICS CORP., a Wyoming corporation (the “Corporation”). Pursuant to authority given by the Corporation’s Article

CS DIAGNOSTICS CORP. CS DIAGNOSTICS GROUP ASSET PURCHASE AGREEMENT

Exhibit 10.2 CS DIAGNOSTICS CORP. Buyer And CS DIAGNOSTICS GROUP Seller ASSET PURCHASE AGREEMENT This Asset Purchase Agreement is by and between CS Diagnostics Corp., a Wyoming Corp., CS Diagnostics Pharma GmbH, an German registered Company; CS Interpharm LLC, a Dubai, UAE limited liability partnership (collectively referred to “CS Diagnostics Corp”), is entered into with an effective date of 4th

CS DIAGNOSTICS CORP.

Exhibit 99.1 CS DIAGNOSTICS CORP. State of Incorporation: Wyoming I.R.S. Employer Identification No.: 20-1290331 Principal Executive Offices: Stresemannallee 4b, Neuss 41460, Germany +49 21311510871 www.csdcorp.us [email protected] Securities to be registered pursuant to Section 12(b): None Securities to be registered pursuant to Section 12(g): Common Stock, $0.00001 par value 1 www.csdcorp.us TABLE

U.S. Securities and Exchange Commission

U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 July 24, 2025 Electronically filed through EDGAR Re: CS Diagnostics, Corp. (CSDX) Form 10-12G (File No. 000-29611) Dear Sir or Madam: Pursuant to the Securities Exchange Act of 1934, as amended (the “Securities Act”), CS Diagnostics, Corp. (the “Company”) hereby requests that the Securities

OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 1 of 17 CS DIAGNOSTICS CORP ANNUAL REPORT AND FINANCIALS FOR THE PERIOD ENDING DECEMBER 31, 2023

Exhibit 10.4 OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 1 of 17 CS DIAGNOSTICS CORP ANNUAL REPORT AND FINANCIALS FOR THE PERIOD ENDING DECEMBER 31, 2023 OTC Markets Group Inc. Disclosure Guidelines for the Pink Market (v5 December 18, 2023) Page 2 of 17 Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines CS DIAGNOSTICS CORP, A Wyo

2 CS DIAGNOSTICS agrees that during the term of this Agreement and for a period of two (2) years after the expiration of this Agreement, it will not, without the prior written consent of LACHMAN, solicit, hire, contract with nor engage the services o

Exhibit 10.7 1 CONSULTING AGREEMENT BETWEEN LACHMAN CONSULTANT SERVICES, INC. AND CS DIAGNOSTICS CORP., ON BEHALF OF ITSELF AND ITS AFFILIATES This Consulting Services Agreement (Agreement) is effective as of March 5, 2025, by and between CS DIAGNOSTICS CORP., on behalf of itself and its affiliates, having an address at Stresemannallee 4b, Neuss 41460, Germany, (hereinafter referred to as CS DIAGN

CS DIAGNOSTICS CORP A Wyoming Corporation (the "Company") CERTIFICATE OF DESIGNATION SERIES C PREFERRED STOCK Of the twenty-five million (25,000,000) shares of Preferred Stock, par value $0.00001 per share, authorized pursuant to the Articles of Inco

Exhibit 10.1 CS DIAGNOSTICS CORP A Wyoming Corporation (the "Company") CERTIFICATE OF DESIGNATION SERIES C PREFERRED STOCK Of the twenty-five million (25,000,000) shares of Preferred Stock, par value $0.00001 per share, authorized pursuant to the Articles of Incorporation, as amended, four million (4,000,000) of such shares are hereby designated as "Series C Preferred Stock." The powers, designati

For Office Use Only Wyoming Secretary of State Herschler Building East, Suite 101122 W 25th Street Cheyenne, WY 82002-0020 Ph. 307.777.7311 Email: [email protected] P-Amendment ? Revised June 2021Profit Corporation Articles of Amendment 1. Corporation

Exhibit 10.0 For Office Use Only Wyoming Secretary of State Herschler Building East, Suite 101122 W 25th Street Cheyenne, WY 82002-0020 Ph. 307.777.7311 Email: [email protected] P-Amendment ? Revised June 2021Profit Corporation Articles of Amendment 1. Corporation name:(Name must match exactly to the Secretary of State's records.)is amended as follows: 3.If the amendment provides for an exchange, r

CS Diagnostics Corp.Amendment to Annual Report CSDX 2024 Annual Financial Report for 12/31/2024 originally published through the OTC Disclosure & News Ser-vice on 03/31/2025Explanatory Note:This is an amended annual report which includes the new PCAO

Exhibit 10.3 CS Diagnostics Corp.Amendment to Annual Report CSDX 2024 Annual Financial Report for 12/31/2024 originally published through the OTC Disclosure & News Ser-vice on 03/31/2025Explanatory Note:This is an amended annual report which includes the new PCAOB audit for the year ending 12/31/2024 by our newly engaged PCAOB auditors with Consent.**This coversheet was automatically generated by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(g) of The Securities Exchange Act of 1934 CS DIAGNOSTICS CORP.

Exhibit 99.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(g) of The Securities Exchange Act of 1934 CS DIAGNOSTICS CORP. State of Incorporation: Wyoming I.R.S. Employer Identification No.: 20-1290331 Principal Executive Offices: Stresemannallee 4b, Neuss 41460, Germany +49 21311510871 www.csdcorp.

CS DIAGNOSTICS CORP. CSDX QUARTERLY REPORT AND FINANCIALS FOR THE PERIOD ENDING MARCH 31, 2025

Exhibit 10.2 CS DIAGNOSTICS CORP. CSDX QUARTERLY REPORT AND FINANCIALS FOR THE PERIOD ENDING MARCH 31, 2025 Disclosure Statement Pursuant to the OTCQB Basic Disclosure Guidelines CS DIAGNOSTICS CORP, A Wyoming Corporation, Stresemannallee 4b Neuss, Germany 41460 Telephone +49 (0)2131-151 08 71 http://www.csdcorp.us [email protected] SIC CODE: 2834 QUARTER REPORT For the Period Ending March 31, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(g) of The Securities Exchange Act of 1934 CS DIAGNOSTICS CORP. (Exact name of registrant as specified i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(g) of The Securities Exchange Act of 1934 CS DIAGNOSTICS CORP. (Exact name of registrant as specified in its charter) Wyoming 20-1290331 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Stresemannallee 4b

or pursuant to an exemption there from, or in compliance with Rule 144 promulgated under the Securities Act or to a person related to or an entity affiliated with said Purchaser and other than in compliance with the applicable securities regulation l

Exhibit 10.5 ,SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT, dated as of April 4th , 2022 (this "Agreement") is entered into by and among PatientTrac Limited, an entity organized under the laws of United Kingdom, and its related group, (the "Shareholder"), and CS Diagnostics GmbH, an entity organized under the laws of Ge1many, its successor or assigns, (the "Purchaser"). The par

Page 2 of 4 and constitute the legal, valid and binding obligations of Seller, enforceable in accordance with their terms, except as the same may be limited by (i) bankruptcy, insolvency, moratorium, and other laws of general application affecting th

Exhibit 10.6 Page 1 of 4 CS DIAGNOSTICS CORP. Buyer And CS DIAGNOSTICS GROUP Seller ASSET PURCHASE AGREEMENT This Asset Purchase Agreement is by and between CS Diagnostics Corp., a Wyoming Corp., CS Diagnostics Pharma GmbH, an German registered Company; CS Interpharm LLC, a Dubai, UAE limited liability partnership (collectively referred to "CS Diagnostics Corp"), is entered into with an effective

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (earliest reported date): September 24, 2024 CS DIAGNOSTICS CORP. (Exact name of registrant as specified in its charter) Wyoming 000-29611 20-1290331 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 flash10q-093009.htm QUARTERLY REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29611 FLASHZERO CORP. fka Th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29611 FLASHZERO CORP. (f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29611 FLASHZERO CORP. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29611 FLASHZERO CORP. fka Th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29611 FLASHZERO CORP. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM 10-Q/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM 10-Q/A x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM 10-Q/A

10-Q/A 1 flash10q-063008.htm QUARTERLY REPORT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM 10-Q/A x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29611 FLASHZERO CORP. (f

Articles of Amendment - Name change to FlashZero Corp.

EX-3.2 3 flashex0302.htm ARTICLES OF AMENDMENT NAME CHANGE EXHIBIT 3.2 ARTICLES OF AMENDMENT – NAME CHANGE 1 2 3 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29611 FLASHZERO CORP. (

Articles of Domestication to Wyoming

EXHIBIT 3.1 ARTICLES OF DOMESTICATION TO WYOMING 1 2 3 4